[
  {
    "ts": null,
    "headline": "Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease",
    "summary": "On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term efficacy and safety of Livdelzi. The study showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi (seladelpar) achieved a composite biochemical response (CBR), demonstrating significant improvements in a key measures of PBC progression. Additionally, 41% (15 out of 37) of partic",
    "url": "https://finnhub.io/api/news?id=f52571e80c88542a6fb8d4e55379935f85bfb9dfb519d15498fec25b0b788f28",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731698075,
      "headline": "Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease",
      "id": 131382193,
      "image": "https://media.zenfs.com/en/Benzinga/fa17fef69415d46f43dbb74820aa893b",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term efficacy and safety of Livdelzi. The study showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi (seladelpar) achieved a composite biochemical response (CBR), demonstrating significant improvements in a key measures of PBC progression. Additionally, 41% (15 out of 37) of partic",
      "url": "https://finnhub.io/api/news?id=f52571e80c88542a6fb8d4e55379935f85bfb9dfb519d15498fec25b0b788f28"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Friday when compared to competitors",
    "summary": "Gilead Sciences Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=7ce9c90933c83ae78b2da6db59a31480cf0e69c5a276cad160144c64517f3bcc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731688860,
      "headline": "Gilead Sciences Inc. stock underperforms Friday when compared to competitors",
      "id": 131417142,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=7ce9c90933c83ae78b2da6db59a31480cf0e69c5a276cad160144c64517f3bcc"
    }
  },
  {
    "ts": null,
    "headline": "Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis",
    "summary": "FOSTER CITY, Calif., November 15, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi® (seladelpar) achieved a composite biochemical response (CBR), demonstrating significant improvements in a key measures of PBC progression. Additionally, 41% (15 out of 37) of participants achieved normali",
    "url": "https://finnhub.io/api/news?id=3b20529000c1b8eee8453904870b2b564517157f8b3ec024c485c673bde810e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731686400,
      "headline": "Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis",
      "id": 131374549,
      "image": "https://s.yimg.com/ny/api/res/1.2/UM7fkcoLU1bxlHlV.2QfhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/2ca46e71401d14d2594fafb4c8e5f049",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., November 15, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi® (seladelpar) achieved a composite biochemical response (CBR), demonstrating significant improvements in a key measures of PBC progression. Additionally, 41% (15 out of 37) of participants achieved normali",
      "url": "https://finnhub.io/api/news?id=3b20529000c1b8eee8453904870b2b564517157f8b3ec024c485c673bde810e4"
    }
  }
]